Drugs

Omalizumab Product Approval Information - Licensing Action

Proper name: Omalizumab
Tradename: Xolair
Manufacturer: Genentech, Inc, South San Francisco, CA, License #1048
Indication for Use: For adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids
Approval Date: 6/20/2003
Type of submission: Biologics license application

 


Label (PDF)

Review of Clinical Safety Data (PDF)

Medical Officer's Efficacy Review (PDF)

CMC Review (PDF)

Page Last Updated: 04/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English